Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Ryman Healthcare (RYM) / HY25

PBT up 21.9% but NPAT fell 49.4% on a tax-rate flip

A tax line that flipped from +30.2% to -46.0% drove the NPAT divergence while pre-lease free cash flow stayed below the historical range at -$52.5m.

Healthcare / Retirement living

RYM revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY22 revenue trajectory was $508.8m.

RYM operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY22 operating cash flow was $586m.

RYM working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
  • HY23 RYM: Outside range high operating working-capital movement. $281m; 3-period range $-806.6m to $14.8m. Operating working-capital movement: NZ$281.0m, above normal range; 1/3 prior periods had builds averaging NZ$14.8m, and 2 had releases averaging NZ$-479.6m.
  • HY24 RYM: Outside range low operating working-capital movement. $-806.6m; 3-period range $-152.7m to $281m. Operating working-capital movement: NZ$-806.6m, below normal range; 2/3 prior periods had builds averaging NZ$147.9m, and 1 had releases averaging NZ$-152.7m.
Operating working-capital movement: NZ$-806.6m, below normal range; 2/3 prior periods had builds averaging NZ$147.9m, and 1 had releases averaging NZ$-152.7m.

RYM NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
FY22 npat trajectory was $692.9m.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 12 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$2.3b

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

-0.17

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

44.25x

i

Enterprise value compared with recent EBITDA.

P/FCF

12.41x

i

Market cap compared with recent free cash flow.

P/B

0.57x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
28 November 2024
Published
28 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY25 vs HY24

Revenue

$366.3m

+13.4% ↑ vs $323m

EBITDA

—

— vs $146.3m

Net profit after tax

$94.4m

-49.4% ↓ vs $186.7m

Net cash inflow from operating activities

$282.8m

-16.3% ↓ vs $337.9m

Declared dividend per share

0.0c

flat vs 0.0c

Profit before tax

$174.8m

+21.9% ↑ vs $143.4m

Cash and cash equivalents

$22.6m

-32.2% ↓ vs $33.3m

Total assets

$12.8b

-2.1% ↓ vs $13.1b

What changed

PBT rose 21.9% to $174.8m — above Annolyse's historical baseline range (3-period mean -59.3%)

NPAT fell 49.4% to $94.4m as the effective tax rate flipped from +30.2% to -46.0%, opening a 71.3pp gap between PBT and NPAT growth. Revenue grew 13.4% to $366.3m, within the historical range (mean 13.8%). Pre-lease free cash flow improved to -$52.5m from -$158.4m but remained below the historical baseline (mean +$104.9m, range +$51.8m to +$206.7m). Operating cash flow fell 16.3% to $282.8m while capex rose 138.8% to $313.3m, taking capex intensity to 85.6% of revenue. Total equity declined 11.6% to $4.3b, gross borrowings rose 3.2% to $2.6b, and ROE compressed to 2.2% from 3.8%. No interim dividend was declared.

What matters

The tax line distorts the headline

PBT growth of 21.9% is the cleaner operating read; the 49.4% NPAT decline reflects the tax flip, not operating deterioration. The release also discloses an "IFRS profit before tax and fair-value movements" (PBTF) of -$79.8m versus -$17.8m prior, which suggests the underlying result excluding fair-value gains actually worsened. The reported PBT improvement therefore relies materially on fair-value movements rather than trading performance.

Cash quality is weak in absolute terms. Pre-lease FCF of -$52.5m is below Annolyse's historical range (mean +$104.9m). OCF fell 16.3% while capex more than doubled to consume 85.6% of revenue. The headline improvement against the -$158.4m prior comparable is real, but the absolute level signals that development spending is outpacing internal cash generation by a wider margin than recent baseline periods.

The balance sheet is absorbing the gap. Equity fell 11.6% to $4.3b as gross borrowings rose to $2.6b. ROE almost halved to 2.2% from 3.8%. With dividends held at zero, capital is being directed to the development pipeline at the expense of shareholder return metrics, which matters because rising leverage and falling returns together compress headroom for any further fair-value impairments.

Expectations

No formal targets were supplied with this release

Annolyse's second-half shape data shows HY24 represented 46.8% of FY24 revenue, indicating modest second-half topline weighting. NPAT seasonality is unreliable: HY24 contributed 3,909% of FY24 NPAT because H2 FY24 was deeply loss-making, so the prior shape is not a usable run-rate. Annualised current revenue of $732.5m would imply mid-single-digit full-year revenue growth from the FY24 base of $689.9m. The release does not support a firm view on full-year NPAT given the dependency on fair-value movements and the step-up in capex commitment.

Quality of result

Earnings quality is mixed

The PBT growth above the historical baseline range is genuine, but the disclosed PBTF deterioration (-$79.8m versus -$17.8m) indicates fair-value movements are doing meaningful work in the headline. The effective tax rate sits below Annolyse's historical range, making NPAT a poor proxy for operating progress this period.

Cash quality is the clearer concern. With OCF down 16.3% and capex up 138.8%, pre-lease FCF of -$52.5m sits below the historical range despite improving on prior comparable. The receivable days movement to 10.6 days is at the lower edge of historical range, so the debtor side is benign, but operating working capital still absorbed $14.8m and inventory days fell to 0.9 from 4.7. With zero dividend and equity declining 11.6%, the development pipeline is being funded by drawing on the balance sheet rather than internal cash flow, which limits durability if fair-value tailwinds reverse.

Unresolved

Open questions

Why did the effective tax rate flip from +30.2% to -46.0%, and how much relates to deferred tax on fair-value movements rather than cash tax payable?
How does management reconcile reported PBT growth of 21.9% with PBTF deteriorating to -$79.8m, and which is the better forward indicator of trading?
What is the trajectory for capex intensity at 85.6% of revenue, and when does pre-lease free cash flow return to positive territory?
Why did equity fall 11.6% while gross borrowings rose, and what does that imply for gearing covenants and rating headroom?
When is the interim dividend likely to be reinstated given the zero payout and ROE compression to 2.2%?

This briefing cannot assess the underlying property-level fair-value assumptions or the project-level economics driving the development capex step-up.

Chat

Ask about RYM HY25

Ask follow-up questions about Ryman Healthcare's HY25 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about RYM HY25

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Ryman Healthcare's HY25 result.

Why did the effective tax rate flip from +30.2% to -46.0%, and how much relates to deferred tax on fair-value movements rather than cash tax payable?Why does "The tax line distorts the headline" matter?How strong was the cash and earnings quality in HY25?What should I watch next for RYM after HY25?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Ryman Healthcare Limited - Announcement Numbers - 30 September 2024

HY25 / results announcement↗

Ryman Healthcare Limited - Consolidated Interim Financial Statements - 30 September 2024

HY25 / financial report↗

Ryman Healthcare Limited - Media Release - 30 September 2024

HY25 / media release↗

Ryman Healthcare Limited - Results Presentation - 30 September 2024

HY25 / results presentation↗

Prior comparable period

Ryman Healthcare Limited - Announcement Numbers and Financial Statements - 30 September 2023

HY24 / financial report↗

Ryman Healthcare Limited - Media Release and Key Statistics - 30 September 2023

HY24 / media release↗

Full-year context

FY24 Result Press Release_FINAL

FY24 / results announcement↗

FY24 Result Press Release_FINAL

FY24 / results release↗

Ryman Healthcare Limited – Financial Statements – 31 March 2024 (including Deloitte Audit Report)

FY24 / financial report↗

Release context

Ryman Healthcare Limited - 1H25 Results Webcast Replay

HY25 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 71.3pp, with a distortion flag in the result.

→

Dividend coverage and payout pressure

Dividend payout versus NPAT is 0.0%.

→

Revenue growth context

Revenue growth was 13.4% for this reporting period.

→

ROE and capital efficiency

ROE was 2.2%, -1.6pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when RYM publishes next

Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.